• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Ingevity Corporation (Amendment)

    2/28/24 5:30:32 PM ET
    $NGVT
    Major Chemicals
    Industrials
    Get the next $NGVT alert in real time by email
    SC 13D/A 1 p24-1051sc13da.htm INGEVITY CORP
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Ingevity Corporation

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    45688C107

    (CUSIP Number)
     
    Philippe B. Pradel
    Inclusive Capital Partners, L.P.
    1170 Gorgas Avenue
    San Francisco, CA 94129
     
    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.
    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    February 26, 2024

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

    (Page 1 of 5 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 45688C107SCHEDULE 13D/APage 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    Inclusive Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY

    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    1,151,405

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    1,151,405

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,151,405

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

    14

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

    CUSIP No. 45688C107SCHEDULE 13D/APage 3 of 5 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Jeffrey W. Ubben

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY

    4

    SOURCE OF FUNDS

    OO

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7

    SOLE VOTING POWER

    0

    8

    SHARED VOTING POWER

    1,151,405

    9

    SOLE DISPOSITIVE POWER

    0

    10

    SHARED DISPOSITIVE POWER

    1,151,405

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,151,405

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.2%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 45688C107SCHEDULE 13D/APage 4 of 5 Pages

      

    The following constitutes Amendment No. 3 to the Schedule 13D filed by the undersigned (“Amendment No. 3”). This Amendment No. 3 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D, as amended.  This Amendment No. 3 amends Items 5(a)-(c), and (e) and 6 as set forth below.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
      Items 5(a)-(c), and (e) of the Schedule 13D are hereby amended and restated as follows:
       
    (a) See rows (11) and (13) of the cover pages to this Amendment No. 3 for the aggregate number of Shares and percentages of the Shares beneficially owned by each Reporting Person. The percentages used in this Amendment No. 3 are calculated based upon 36,235,885 Shares outstanding as of February 14, 2024, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed by the Issuer with the Securities and Exchange Commission on February 22, 2024.
       
    (b) See rows (7) through (10) of the cover pages to this Amendment No. 3 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) On February 26, 2024, the In-Cap Funds sold 1,250,000 Shares pursuant to a block trade with J.P. Morgan Securities LLC at a price of $46.00 per Share. Other than as disclosed herein, no transactions in the Shares have been effected by the Reporting Persons in the past sixty (60) days.
       
    (e) February 26, 2024.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
       
      Item 6 of the Schedule 13D is hereby amended and supplemented by the addition of the following:
       
      Mr. Slocum holds a total of 5,034 vested and unvested deferred stock units (“DSUs”) pursuant to his election to receive DSUs in lieu of the annual non-employee director restricted stock unit grant and quarterly director fees.
       
      These DSUs will settle into an equal number of the Issuer’s Shares upon Mr. Slocum’s termination of board service pursuant to the Issuer’s Non-Employee Director Deferred Compensation Plan and 2016 Omnibus Incentive Plan, as amended. Mr. Slocum is deemed to hold the Shares for the benefit of the In-Cap Funds and indirectly for the benefit of In-Cap, and may, after vesting, if applicable, transfer the Shares directly to the In-Cap Funds.

     

    CUSIP No. 45688C107SCHEDULE 13D/APage 5 of 5 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 28, 2024

     

      Inclusive Capital Partners, L.P.
       
      By: /s/  Philippe B. Pradel
      Name: Philippe B. Pradel
      Title: Chief Compliance Officer
       
       
      /s/  Jeffrey W. Ubben
      JEFFREY W. UBBEN

     

     

    Get the next $NGVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NGVT

    DatePrice TargetRatingAnalyst
    2/26/2025$62.00 → $65.00Market Perform → Outperform
    BMO Capital Markets
    8/7/2024$58.00Market Perform → Market Outperform
    CJS Securities
    4/22/2024$52.00 → $62.00Hold → Buy
    Jefferies
    11/6/2023$49.00Market Outperform → Market Perform
    CJS Securities
    10/3/2023$62.00 → $53.00Buy → Hold
    Loop Capital
    8/7/2023$71.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/27/2023$64.00 → $75.00Hold → Buy
    Loop Capital
    5/5/2023$92.00 → $64.00Buy → Hold
    Loop Capital
    More analyst ratings

    $NGVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Leadership Updates

    Live Leadership Updates

    See more
    • Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

      Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

      3/20/25 5:34:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces appointment of David H. Li as president and CEO

      Li brings 25-year+ record of driving successful corporate transformation, long-term growth and stockholder value creation at premier global specialty materials supplier Ingevity Corporation (NYSE:NGVT) today announced that its board of directors has appointed David H. Li as the company's president and CEO, effective as of April 7, 2025, and that he is expected to join the board of directors following the 2025 Annual Meeting. Li succeeds Ingevity board member, Luis Fernandez-Moreno, who has been serving as interim president and CEO since October 2024. Fernandez-Moreno will remain on Ingevity's board. This press release features multimedia. View the full release here: https://www.businesswir

      3/10/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity Highlights Significant Momentum on Actions Underway to Drive Improved Performance and Value Creation

      Delivered Record Year in Performance Materials and Strategic Repositioning in Performance Chemicals Is Already Demonstrating Results Business Portfolio Review Is Progressing with Recently Announced Strategic Alternatives Process for Industrial Specialties Product Line and Evaluation of Additional Portfolio and Cost Reduction Actions Ongoing Provides Information About Engagement with Vision One Ingevity Corporation (NYSE:NGVT) today issued the following letter to stockholders in response to the presentation issued by Vision One Management Partners ("Vision One") earlier today: Dear Ingevity Stockholders, The Ingevity Board of Directors and leadership team are committed to taking ag

      2/25/25 4:21:00 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    SEC Filings

    See more
    • SEC Form S-8 filed by Ingevity Corporation

      S-8 - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:16:03 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Ingevity Corporation

      S-8 POS - Ingevity Corp (0001653477) (Filer)

      5/7/25 4:15:57 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form 10-Q filed by Ingevity Corporation

      10-Q - Ingevity Corp (0001653477) (Filer)

      5/6/25 4:24:35 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blackwell Jean was granted 4,057 shares, increasing direct ownership by 145% to 6,857 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:42:08 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Fernandez-Moreno Luis M was granted 4,057 shares, increasing direct ownership by 8% to 53,105 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:38:06 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Director Lynch Frederick J was granted 4,057 shares, increasing direct ownership by 18% to 26,359 units (SEC Form 4)

      4 - Ingevity Corp (0001653477) (Issuer)

      5/5/25 6:33:42 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ingevity upgraded by BMO Capital Markets with a new price target

      BMO Capital Markets upgraded Ingevity from Market Perform to Outperform and set a new price target of $65.00 from $62.00 previously

      2/26/25 7:15:06 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by CJS Securities with a new price target

      CJS Securities upgraded Ingevity from Market Perform to Market Outperform and set a new price target of $58.00

      8/7/24 9:18:13 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity upgraded by Jefferies with a new price target

      Jefferies upgraded Ingevity from Hold to Buy and set a new price target of $62.00 from $52.00 previously

      4/22/24 7:39:26 AM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/12/24 3:54:24 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

      SC 13G/A - Ingevity Corp (0001653477) (Subject)

      11/4/24 11:52:25 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Ingevity Corporation (Amendment)

      SC 13D/A - Ingevity Corp (0001653477) (Subject)

      2/28/24 5:30:32 PM ET
      $NGVT
      Major Chemicals
      Industrials

    $NGVT
    Financials

    Live finance-specific insights

    See more
    • Ingevity reports first quarter 2025 financial results

      HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

      5/5/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity announces dates for first-quarter 2025 earnings release and webcast

      Ingevity Corporation (NYSE:NGVT) announced today that it will release its first-quarter 2025 earnings after the stock market close on Monday, May 5, 2025. The company will host a live webcast on Tuesday, May 6, at 9:00 a.m. (Eastern) to discuss first-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 815699. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on May 6, 2025, through M

      4/24/25 9:00:00 AM ET
      $NGVT
      Major Chemicals
      Industrials
    • Ingevity reports fourth quarter and full year 2024 financial results

      Fourth Quarter: Net sales of $298.8 million decreased 20% compared to prior year primarily due to repositioning actions in the Performance Chemicals segment that resulted in the exit of lower-margin end markets Net income of $16.6 million and diluted earnings per share (EPS) of $0.46, including pre-tax restructuring charges of $23.4 million; adjusted earnings of $34.7 million and diluted adjusted EPS of $0.95 Adjusted EBITDA of $80.6 million and adjusted EBITDA margin of 27.0% Operating cash flow of $64.5 million and free cash flow of $39.6 million, which included the second and final $50.0 million installment of a termination fee for a long-term crude tall oil (CTO) supply agreemen

      2/18/25 4:15:00 PM ET
      $NGVT
      Major Chemicals
      Industrials